Payment Terms for Intermediates: 7 Buyer Mistakes to Avoid
This guide compares T/T, L/C, D/P and D/A for pharmaceutical intermediate purchases, with worked costs on a $60,000 order and the seven mistakes buyers make.
August 21, 2026
(S)-1-(4-fluoro-2-methyl-2H-indazol-5-yl)-3-(2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-1H-imidazol-2(3H)-one
Orforglipron intermediates；(S)-1-(4-F-2-Me-indazol-5-yl)-3-(2-(4-F-3,5-diMe-phenyl)-4-Me-tetrahydropyrazolo[4,3-c]pyridin-3-yl)-imidazol-2-one
CAS: 2212022-56-3
Chemical Formula: C₂₆H₂₅F₂N₇O
Molecular Weight: 489.52
Availability: R&D; Commercialization
Orforglipron Intermediates
⬤ CAS No.2212022-56-3
⬤ Our Packaging type：
20kg barrel；5kg barrel；1kg bag；500g bag ; Customized Packaging
| Product Name | (S)-1-(4-fluoro-2-methyl-2H-indazol-5-yl)-3-(2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-1H-imidazol-2(3H)-one |
| CAS.No | 2212022-56-3 |
| Molecular Formula | C₂₆H₂₅F₂N₇O |
| Molecular Weight | 489.52 |
| Related Categories | This compound is often used in drug development, especially as a key intermediate in the synthesis of Orforglipron molecules |
| Appearance | Usually white to off-white solid |
| Boiling Point | About 650°C |
| Density | 1.45±0.1 g/cm³(Predicted) |
| Acidity coefficient (pKa) | 8.39±0.40(Predicted) |
| Precautions | This product is a research chemical and cannot be used directly on the human body. |
| Personal Protection | This product is a chemical synthesis product and may be irritating. Protective equipment (such as gloves, goggles, and lab coats) must be worn when handling it. |
| Storage Conditions | Store sealed and dry at -20°C, away from light and moisture. Use as soon as possible after opening. Remaining samples must be resealed and labeled. |
| R&D purposes | This product is a high-purity pharmaceutical intermediate, mainly used in the following research and development areas, as a key intermediate for the treatment of anabolic diseases (such as diabetes, obesity), especially for the construction of non-peptide GLP-1 receptor agonists (such as Orforglipron analogs) |
| Application | Used as key intermediates to synthesize molecules with specific biological activities, such as drugs for metabolic diseases such as diabetes and obesity (such as orforglipron analogs) |
Customer Reviews
Real customer feedback
Michael Carter
Reliable Global Partner
“Tianming Pharmaceutical has redefined reliability for us. Their ability to deliver high-potency APIs and intermediates under tight deadlines—is unmatched. The team’s transparency in documentation and proactive updates make them a stress-free partner. A true backbone for our operations!”
March 18, 2024
Dr. Sofia Alvarez
Outstanding Technical Guidance
“Few suppliers align so perfectly with EU GMP requirements. Tianming’s commitment to audit-ready quality systems, batch traceability, and purity consistency has streamlined our production processes. Their diligence eliminates regulatory risks—a rare advantage in today’s market.”
February 15, 2024
Rajesh Kapoor
Beyond Supplier, A Solutions Partner
“Tianming’s technical team doesn’t just deliver materials—they solve problems. When we faced stability challenges with a niche compound, their scientists proposed a tailored purity adjustment that saved our project timeline. Their agility transforms obstacles into opportunities.”
June 15, 2024
Emily Zhang
Strategic Growth Ally
“Over 5+ years, Tianming has consistently adapted to our evolving needs—whether scaling volumes or supporting custom synthesis projects. Their ethical pricing models and long-term vision make them more than a vendor; they’re integral to our competitive edge.”
April 27, 2024
What's News
Latest news at Tianming
Impurity Fate Mapping: 5 Documents Buyers Should Request
An impurity absent from a Certificate of Analysis is not necessarily absent from the process — it may simply have been purged downstream. This guide explains impurity fate mapping, purge factors, ICH M7 Option 4, and the five documents buyers should request.
August 19, 2026
Dual Sourcing for API Intermediates: A Buyer’s Qualification Checklist
This checklist shows buyers how to qualify a second supplier in six steps — documentation, batch consistency, quality agreements, and activation triggers included.
August 14, 2026
Still Have Questions？
If you still have questions or need more information, our team is here to help. Please don’t hesitate to contact us for personalized assistance.